Zimmer Biomet reports Q4 earnings beat, revenue up 4.3%

Published 06/02/2025, 12:52
Zimmer Biomet reports Q4 earnings beat, revenue up 4.3%

WARSAW, Ind. - Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported fourth quarter earnings that slightly exceeded analyst expectations, with revenue growth driven by strong performance across its product portfolio.

The medical device company posted adjusted earnings per share of $2.31 for Q4, edging past the analyst consensus of $2.30. Revenue for the quarter came in at $2.023 billion, up 4.3% YoY and ahead of estimates of $2.01 billion. On a constant currency basis, revenue increased 4.9% compared to the prior year period.

For the full year 2024, Zimmer Biomet reported net sales of $7.679 billion, representing a 3.8% increase YoY, or 4.8% growth on a constant currency basis. Full-year adjusted diluted EPS was $8.00.

"We are pleased with our fourth quarter results and strong performance to close 2024, delivering on our financial guidance and validating the solid work that the team is doing across the globe," said Ivan Tornos, Zimmer Biomet’s President and CEO.

Looking ahead, the company provided guidance for fiscal year 2025, projecting adjusted EPS in the range of $8.15 to $8.35. This outlook falls below the current analyst consensus of $8.55 per share.

Zimmer Biomet highlighted several recent developments, including its agreement to acquire Paragon 28, a foot and ankle orthopedics company, as part of its strategy to diversify beyond core orthopedics.

The company also received FDA approvals for new shoulder and knee implant systems during the quarter.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.